Analysis of the drug target of the anti-tuberculosis compound OCT313: phosphotransacetylase is a potential drug target for anti-mycobacterial agents
Open Access
- 23 December 2025
- journal article
- Published by American Society for Microbiology in mSphere
- Vol. 10 (12) , e0046325
Abstract
Tuberculosis (TB) is one of the most common infectious diseases caused by bacteria worldwide. The increasing prevalence of multidrug-resistant TB (MDR-TB) and latent TB infection (LTBI) has intensified the global TB burden. Therefore, the development of new drugs for MDR-TB and LTBI is urgently required. We have reported that the derivative of dithiocarbamate sugar derivative, 2-acetamido-2-deoxy-β-D-glucopyranosyl N,N -dimethyldithiocarbamate (OCT313), exhibits anti-mycobacterial activity against MDR-MTB. Here, we identified the target of OCT313. In experimentally generated OCT313-resistant bacteria, adenine at position 1,092 in the metabolic enzyme phosphotransacetylase (PTA) gene was replaced with cytosine. This mutation is a nonsynonymous mutation that converts methionine to leucine at position 365 in the PTA protein. OCT313 inhibited the enzymatic activity of recombinant wild-type PTA, but not of the mutant PTA (M365L). PTA is an enzyme that produces acetyl-coenzyme A (acetyl-CoA) from acetyl phosphate and CoA and is involved in metabolic pathways; therefore, it was expected to also be active against dormant Mycobacterium tuberculosis bacilli. OCT313 exhibits antibacterial activity in the Wayne model of dormancy using Mycobacterium bovis BCG, and overexpression of PTA in OCT313-resistant bacilli restored sensitivity to OCT313. Collectively, the target of OCT313 is PTA, and OCT313 is a promising antimicrobial candidate for MDR-TB and LTBI. IMPORTANCE: Through this study, we propose a new target for the development of medicines to treat multidrug-resistant tuberculosis and latent tuberculosis infection. The target enzyme phosphotransacetylase (PTA) is a key enzyme that functions in major metabolic pathways, and the homologous structures of PTA enzymes vary greatly among bacterial species. Since the treatment of mycobacterial disease is long term, the development of antibiotics targeting PTA is useful for species-specific therapy.Keywords
Funding Information
- Japan Society for the Promotion of Science (20K07125, 24K09872)
- Japan Agency for Medical Research and Development (JP21fk0108590, JP23fk0108591, JP223fa627005)
This publication has 32 references indexed in Scilit:
- Exploring phytochemicals and marine natural products as alternative therapeutic agents targeting phosphotransacetylase (PTA) in Mycobacterium tuberculosis: An underexplored drug targetJournal of Molecular Graphics and Modelling, 2025
- Control of central metabolism’s architecture in Escherichia coli: An overviewMicrobiological Research, 2022
- Corrigendum to “Mechanisms of resistance to delamanid, a drug for Mycobacterium tuberculosis” [Tuberculosis 108 (January 2018) 186–194]Tuberculosis, 2018
- Synthesis and evaluation of anti-tubercular activity of new dithiocarbamate sugar derivativesBioorganic & Medicinal Chemistry Letters, 2011
- Synthesis of new sugar derivatives and evaluation of their antibacterial activities against Mycobacterium tuberculosisBioorganic & Medicinal Chemistry Letters, 2009
- Whole genome sequence analysis of Mycobacterium bovis bacillus Calmette–Guérin (BCG) Tokyo 172: A comparative study of BCG vaccine substrainsVaccine, 2009
- Acetate kinase: not just a bacterial enzymeTrends in Microbiology, 2006
- Control of carbon flux through enzymes of central and intermediary metabolism during growth of Escherichia coli on acetateCurrent Opinion in Microbiology, 2006
- Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assaysJournal of Immunological Methods, 1983
- [59] Phosphotransacetylase from Clostridium kluyveri1969